1. Home
  2. BCDA vs HUGE Comparison

BCDA vs HUGE Comparison

Compare BCDA & HUGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BCDA
  • HUGE
  • Stock Information
  • Founded
  • BCDA N/A
  • HUGE 1998
  • Country
  • BCDA United States
  • HUGE Canada
  • Employees
  • BCDA N/A
  • HUGE N/A
  • Industry
  • BCDA Biotechnology: Pharmaceutical Preparations
  • HUGE Biotechnology: Pharmaceutical Preparations
  • Sector
  • BCDA Health Care
  • HUGE Health Care
  • Exchange
  • BCDA Nasdaq
  • HUGE Nasdaq
  • Market Cap
  • BCDA 9.4M
  • HUGE 7.8M
  • IPO Year
  • BCDA N/A
  • HUGE N/A
  • Fundamental
  • Price
  • BCDA $2.87
  • HUGE $0.14
  • Analyst Decision
  • BCDA Strong Buy
  • HUGE
  • Analyst Count
  • BCDA 1
  • HUGE 0
  • Target Price
  • BCDA $60.00
  • HUGE N/A
  • AVG Volume (30 Days)
  • BCDA 85.1K
  • HUGE 2.5M
  • Earning Date
  • BCDA 08-07-2024
  • HUGE 09-12-2024
  • Dividend Yield
  • BCDA N/A
  • HUGE N/A
  • EPS Growth
  • BCDA N/A
  • HUGE N/A
  • EPS
  • BCDA N/A
  • HUGE N/A
  • Revenue
  • BCDA $468,000.00
  • HUGE N/A
  • Revenue This Year
  • BCDA N/A
  • HUGE N/A
  • Revenue Next Year
  • BCDA $436.41
  • HUGE N/A
  • P/E Ratio
  • BCDA N/A
  • HUGE N/A
  • Revenue Growth
  • BCDA N/A
  • HUGE N/A
  • 52 Week Low
  • BCDA $2.62
  • HUGE $0.13
  • 52 Week High
  • BCDA $34.80
  • HUGE $1.68
  • Technical
  • Relative Strength Index (RSI)
  • BCDA 36.31
  • HUGE 29.78
  • Support Level
  • BCDA $2.85
  • HUGE $0.14
  • Resistance Level
  • BCDA $3.66
  • HUGE $0.16
  • Average True Range (ATR)
  • BCDA 0.30
  • HUGE 0.02
  • MACD
  • BCDA 0.07
  • HUGE 0.01
  • Stochastic Oscillator
  • BCDA 8.65
  • HUGE 24.41

About BCDA BioCardia Inc.

BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with significant unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an "off the shelf" cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).

About HUGE FSD Pharma Inc. Class B Subordinate Voting Shares

FSD Pharma Inc is a biopharmaceutical company developing three clinical candidates with the potential to address neuropsychiatric, neurodegenerative, and inflammatory disorders. Along with its subsidiaries, the group is focused on pharmaceutical research and development of its compound, FSD201, an ultra-micronized PEA, for the treatment of inflammatory diseases; Lucid-Psych is used in the treatment of mental health disorders and Lucid-MS is used in the treatment of neurodegenerative disorders. The company operates in two segments: Biopharmaceutical and Strategic Investments.

Share on Social Networks: